Cogent Biosciences to Participate in the Guggenheim Biotech Conference
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Wednesday, February 5, 2025 at 9:30 a.m. ET in New York.
Interested parties can access a live webcast of the presentation through the Investors & Media section of Cogent's website. The presentation recording will be made available approximately two hours after the event and will remain accessible for 30 days on the company's investor relations platform.
Cogent Biosciences (Nasdaq: COGT), un'azienda biotecnologica che si specializza in terapie di precisione per malattie geneticamente definite, ha annunciato la sua prossima partecipazione alla Guggenheim SMID Cap Biotech Conference. L'azienda parteciperà a una chiacchierata informale programmata per mercoledì 5 febbraio 2025 alle 9:30 AM ET a New York.
Le parti interessate possono accedere a una trasmissione web in diretta della presentazione tramite la sezione Investitori & Media del sito web di Cogent. La registrazione della presentazione sarà disponibile circa due ore dopo l'evento e rimarrà accessibile per 30 giorni sulla piattaforma di relazioni con gli investitori dell'azienda.
Cogent Biosciences (Nasdaq: COGT), una compañía biotecnológica especializada en terapias de precisión para enfermedades genéticamente definidas, ha anunciado su próxima participación en la Guggenheim SMID Cap Biotech Conference. La compañía participará en una charla informal programada para el miércoles 5 de febrero de 2025 a las 9:30 AM ET en Nueva York.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Inversores y Medios en el sitio web de Cogent. La grabación de la presentación estará disponible aproximadamente dos horas después del evento y permanecerá accesible durante 30 días en la plataforma de relaciones con inversores de la empresa.
Cogent Biosciences (Nasdaq: COGT)는 유전적으로 정의된 질병을 위한 정밀 치료를 전문으로 하는 생명공학 회사로, Guggenheim SMID Cap Biotech Conference에 참여한다고 발표했습니다. 이 회사는 2025년 2월 5일 수요일 오전 9시 30분 ET에 뉴욕에서 예정된 간담회에 참여할 것입니다.
관심 있는 당사자는 Cogent 웹사이트의 투자자 및 미디어 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 약 2시간 후에 이용 가능하며, 회사의 투자자 관계 플랫폼에서 30일 동안 접속할 수 있습니다.
Cogent Biosciences (Nasdaq: COGT), une entreprise de biotechnologie spécialisée dans les thérapies de précision pour les maladies génétiquement définies, a annoncé sa prochaine participation à la Guggenheim SMID Cap Biotech Conference. L'entreprise participera à une conversation informelle prévue pour le mercredi 5 février 2025 à 9h30 ET à New York.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs & Médias du site Web de Cogent. L'enregistrement de la présentation sera disponible environ deux heures après l'événement et restera accessible pendant 30 jours sur la plateforme des relations investisseurs de l'entreprise.
Cogent Biosciences (Nasdaq: COGT), ein Biotechnologieunternehmen, das sich auf präzise Therapien für genetisch definierte Krankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference angekündigt. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der für Mittwoch, den 5. Februar 2025 um 9:30 Uhr ET in New York geplant ist.
Interessierte Parteien können über den Bereich Investoren & Medien auf der Website von Cogent auf einen Live-Webcast der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird etwa zwei Stunden nach der Veranstaltung verfügbar sein und für 30 Tage auf der Plattform für Investor Relations des Unternehmens zugänglich bleiben.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Wednesday, February 5, 2025 at 9:30 a.m. ET.
A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of the events and will be archived for up to 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
When is Cogent Biosciences (COGT) presenting at the Guggenheim Biotech Conference 2025?
How can investors watch Cogent Biosciences' (COGT) Guggenheim Conference presentation?
How long will the replay of COGT's Guggenheim Conference presentation be available?
What type of therapies does Cogent Biosciences (COGT) focus on developing?
